ECS Botanics Ventures into Direct Consumer Sales
Company Announcements

ECS Botanics Ventures into Direct Consumer Sales

Ecs Botanics Holdings Ltd (AU:ECS) has released an update.

ECS Botanics Holdings Ltd has initiated a direct-to-consumer strategy with its first B2C medicinal cannabis contract under the ‘RAP’ brand, aiming for a minimum of $380,000 in annual sales. The company has expanded its GMP license to include a wider range of products, such as gummies and soft gel capsules, and has begun commercial shipments to Germany. To support the launch, ECS has also recruited an experienced B2C sales team and expects revenue growth and increased margins in 2025.

For further insights into AU:ECS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskEcs Botanics Holdings Ltd Announces Security Consolidation Update
TipRanks Australian Auto-Generated NewsdeskECS Botanics Updates Consolidation Timetable Amidst Expansion
TipRanks Australian Auto-Generated NewsdeskEcs Botanics Announces Security Consolidation Plan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App